# HealthLynked Corp: financial statements, quarterly

HLYK · OTC · CIK 1680139 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hlyk.md) · [Financials](/companies/hlyk/financials.md) · [Filings](/companies/hlyk/filings.md) · [Insiders](/companies/hlyk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hlyk/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [1,333](/filings/0001213900-24-098383.md) | [931 d](/filings/0001213900-25-026262.md) | [1,004](/filings/0001213900-24-043561.md) | [795](/filings/0001213900-24-068949.md) | [590](/filings/0001213900-24-098383.md) | [619 d](/filings/0001213900-25-026262.md) | [774](/filings/0001213900-26-057581.md) | [592](/filings/0001213900-26-090221.md) | [389](/filings/0001213900-25-112578.md) | [310 d](/filings/0001213900-26-037499.md) | [423](/filings/0001213900-26-057581.md) | [250](/filings/0001213900-26-090221.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $k | [768](/filings/0001213900-24-098383.md) | [918 d](/filings/0001213900-25-026262.md) | [999](/filings/0001213900-25-044233.md) | [861](/filings/0001213900-25-076656.md) | [632](/filings/0001213900-25-112578.md) | [546 d](/filings/0001213900-26-037499.md) | [629](/filings/0001213900-26-057581.md) | [452](/filings/0001213900-26-090221.md) | [501](/filings/0001213900-25-112578.md) | [454 d](/filings/0001213900-26-037499.md) | [847](/filings/0001213900-26-057581.md) | [517](/filings/0001213900-26-090221.md) |
| Operating income | $k | [(1,185)](/filings/0001213900-24-098383.md) | [(1,112) d](/filings/0001213900-25-026262.md) | [(1,178)](/filings/0001213900-25-044233.md) | [(1,079)](/filings/0001213900-25-076656.md) | [(1,671)](/filings/0001213900-25-112578.md) | [(749) d](/filings/0001213900-26-037499.md) | [(617)](/filings/0001213900-26-057581.md) | [(435)](/filings/0001213900-26-090221.md) | [(530)](/filings/0001213900-25-112578.md) | [(531) d](/filings/0001213900-26-037499.md) | [(701)](/filings/0001213900-26-057581.md) | [(539)](/filings/0001213900-26-090221.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(175)](/filings/0001213900-24-098383.md) | [(1,286) d](/filings/0001213900-25-026262.md) | [(1,388)](/filings/0001213900-25-112578.md) | [(1,540)](/filings/0001213900-25-112578.md) | [(1,973)](/filings/0001213900-25-112578.md) | [(1,230) d](/filings/0001213900-26-037499.md) | [(1,051)](/filings/0001213900-26-090221.md) | [(701)](/filings/0001213900-26-090221.md) | [(852)](/filings/0001213900-25-112578.md) | [(676) d](/filings/0001213900-26-037499.md) | [(1,621)](/filings/0001213900-26-090221.md) | [(820)](/filings/0001213900-26-090221.md) |
| Diluted EPS | $ per share | [0.00](/filings/0001213900-24-098383.md) | not reported | [0.00](/filings/0001213900-25-044233.md) | [(0.01)](/filings/0001213900-25-076656.md) | [(0.70)](/filings/0001213900-25-112578.md) | not reported | [(0.37)](/filings/0001213900-26-057581.md) | [(0.25)](/filings/0001213900-26-090221.md) | [(0.30)](/filings/0001213900-25-112578.md) | not reported | [(0.56)](/filings/0001213900-26-057581.md) | [(0.28)](/filings/0001213900-26-090221.md) |
| Basic EPS | $ per share | [0.00](/filings/0001213900-24-098383.md) | not reported | [0.00](/filings/0001213900-25-044233.md) | [(0.01)](/filings/0001213900-25-076656.md) | [(0.70)](/filings/0001213900-25-112578.md) | not reported | [(0.37)](/filings/0001213900-26-057581.md) | [(0.25)](/filings/0001213900-26-090221.md) | [(0.30)](/filings/0001213900-25-112578.md) | not reported | [(0.56)](/filings/0001213900-26-057581.md) | [(0.28)](/filings/0001213900-26-090221.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [51.3](/filings/0001213900-23-086915.md) | [247](/filings/0001213900-25-026262.md) | [23.5](/filings/0001213900-24-043561.md) | [173](/filings/0001213900-24-068949.md) | [15.0](/filings/0001213900-24-098383.md) | [76.2](/filings/0001213900-25-026262.md) | [22.3](/filings/0001213900-25-044233.md) | [20.2](/filings/0001213900-25-076656.md) | [10.9](/filings/0001213900-25-112578.md) | [37.1](/filings/0001213900-26-037499.md) | [24.0](/filings/0001213900-26-057581.md) | [12.8](/filings/0001213900-26-090221.md) |
| Current assets | $k | [2,202](/filings/0001213900-23-086915.md) | [656](/filings/0001213900-25-026262.md) | [1,896](/filings/0001213900-24-043561.md) | [2,006](/filings/0001213900-24-068949.md) | [1,824](/filings/0001213900-24-098383.md) | [1,641](/filings/0001213900-26-037499.md) | [1,568](/filings/0001213900-25-044233.md) | [1,559](/filings/0001213900-25-076656.md) | [1,543](/filings/0001213900-25-112578.md) | [1,552](/filings/0001213900-26-090221.md) | [1,539](/filings/0001213900-26-057581.md) | [1,545](/filings/0001213900-26-090221.md) |
| Total assets | $k | [5,689](/filings/0001213900-24-098383.md) | [4,280](/filings/0001213900-25-026262.md) | [3,891](/filings/0001213900-24-043561.md) | [3,860](/filings/0001213900-24-068949.md) | [2,758](/filings/0001213900-24-098383.md) | [2,223](/filings/0001213900-26-037499.md) | [2,057](/filings/0001213900-26-057581.md) | [1,848](/filings/0001213900-26-090221.md) | [1,765](/filings/0001213900-25-112578.md) | [1,702](/filings/0001213900-26-090221.md) | [1,626](/filings/0001213900-26-057581.md) | [1,593](/filings/0001213900-26-090221.md) |
| Current liabilities | $k | [3,360](/filings/0001213900-23-086915.md) | [2,412](/filings/0001213900-25-026262.md) | [2,695](/filings/0001213900-24-043561.md) | [3,396](/filings/0001213900-24-068949.md) | [3,807](/filings/0001213900-24-098383.md) | [4,690](/filings/0001213900-26-037499.md) | [5,600](/filings/0001213900-25-044233.md) | [6,126](/filings/0001213900-25-076656.md) | [6,744](/filings/0001213900-25-112578.md) | [7,013](/filings/0001213900-26-090221.md) | [8,198](/filings/0001213900-26-057581.md) | [8,896](/filings/0001213900-26-090221.md) |
| Total liabilities | $k | [4,128](/filings/0001213900-23-086915.md) | [3,475](/filings/0001213900-25-026262.md) | [3,669](/filings/0001213900-24-043561.md) | [4,284](/filings/0001213900-24-068949.md) | [4,691](/filings/0001213900-24-098383.md) | [5,352](/filings/0001213900-26-037499.md) | [6,195](/filings/0001213900-25-044233.md) | [6,601](/filings/0001213900-25-076656.md) | [7,198](/filings/0001213900-25-112578.md) | [7,464](/filings/0001213900-26-090221.md) | [8,648](/filings/0001213900-26-057581.md) | [9,346](/filings/0001213900-26-090221.md) |
| Long-term debt | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $k | [1,561](/filings/0001213900-24-098383.md) | [805](/filings/0001213900-26-037499.md) | [221](/filings/0001213900-25-112578.md) | [(425)](/filings/0001213900-25-112578.md) | [(1,933)](/filings/0001213900-25-112578.md) | [(3,129)](/filings/0001213900-26-090221.md) | [(4,137)](/filings/0001213900-26-090221.md) | [(4,752)](/filings/0001213900-26-090221.md) | [(5,433)](/filings/0001213900-25-112578.md) | [(5,762)](/filings/0001213900-26-090221.md) | [(7,022)](/filings/0001213900-26-090221.md) | [(7,753)](/filings/0001213900-26-090221.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,249) d](/filings/0001213900-24-098383.md) | [(1,192) d](/filings/0001213900-25-026262.md) | [(855)](/filings/0001213900-25-044233.md) | [(859) d](/filings/0001213900-25-076656.md) | [(1,037) d](/filings/0001213900-25-112578.md) | [(744) d](/filings/0001213900-26-037499.md) | [(433)](/filings/0001213900-26-057581.md) | [(418) d](/filings/0001213900-26-090221.md) | [(444) d](/filings/0001213900-25-112578.md) | [(419) d](/filings/0001213900-26-037499.md) | [(222)](/filings/0001213900-26-057581.md) | [(350) d](/filings/0001213900-26-090221.md) |
| Capital expenditure | $k | not reported | [0.0 d](/filings/0001213900-25-026262.md) | [2.6](/filings/0001213900-25-044233.md) | [0.0 d](/filings/0001213900-25-076656.md) | [0.0 d](/filings/0001213900-25-112578.md) | [0.0 d](/filings/0001213900-26-037499.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [243](/filings/0001213900-23-086915.md) | [257](/filings/0001213900-24-043561.md) | [260](/filings/0001213900-24-068949.md) | [266](/filings/0001213900-24-098383.md) | [280](/filings/0001213900-25-044233.md) | [282](/filings/0001213900-25-076656.md) | [2.8](/filings/0001213900-25-112578.md) | [2.8](/filings/0001213900-26-057581.md) | [2.8](/filings/0001213900-26-090221.md) | [2.8](/filings/0001213900-25-112578.md) | [2.9](/filings/0001213900-26-057581.md) | [2.9](/filings/0001213900-26-090221.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,953,225 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-090221.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.